CONMED Corporation (NASDAQ:CNMD) is scheduled to be releasing its earnings data after the market closes on Thursday, November 2nd. Analysts expect CONMED Corporation to post earnings of $0.42 per share for the quarter.

CONMED Corporation (NASDAQ:CNMD) last posted its earnings results on Wednesday, July 26th. The medical technology company reported $0.41 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.41. CONMED Corporation had a net margin of 2.02% and a return on equity of 8.38%. The firm had revenue of $197.20 million for the quarter, compared to the consensus estimate of $194.50 million. During the same period in the previous year, the firm posted $0.47 EPS. The business’s quarterly revenue was up 2.0% on a year-over-year basis. On average, analysts expect CONMED Corporation to post $1.87 EPS for the current fiscal year and $2.03 EPS for the next fiscal year.

Shares of CONMED Corporation (CNMD) opened at 53.15 on Thursday. The stock has a 50 day moving average of $52.03 and a 200-day moving average of $50.46. CONMED Corporation has a 12-month low of $37.60 and a 12-month high of $54.47. The company has a market capitalization of $1.48 billion, a P/E ratio of 95.08 and a beta of 0.68.

The company also recently disclosed a quarterly dividend, which was paid on Thursday, October 5th. Investors of record on Friday, September 15th were given a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a yield of 1.51%. The ex-dividend date was Thursday, September 14th. CONMED Corporation’s payout ratio is currently 142.86%.

CNMD has been the subject of several recent analyst reports. BidaskClub cut shares of CONMED Corporation from a “buy” rating to a “hold” rating in a research report on Thursday, June 29th. Needham & Company LLC raised their price objective on shares of CONMED Corporation from $54.00 to $57.00 and gave the stock a “buy” rating in a research report on Thursday, July 27th. Zacks Investment Research cut shares of CONMED Corporation from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. TheStreet upgraded shares of CONMED Corporation from a “c+” rating to a “b-” rating in a research report on Thursday, August 3rd. Finally, KeyCorp restated a “hold” rating on shares of CONMED Corporation in a research report on Friday, August 25th. Two analysts have rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $49.33.

ILLEGAL ACTIVITY WARNING: This report was first posted by American Banking News and is the property of of American Banking News. If you are accessing this report on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this report can be accessed at

In related news, Director Jo Ann Golden sold 3,000 shares of the firm’s stock in a transaction dated Monday, August 14th. The shares were sold at an average price of $50.00, for a total transaction of $150,000.00. Following the completion of the sale, the director now directly owns 19,782 shares in the company, valued at $989,100. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 2.62% of the stock is currently owned by company insiders.

About CONMED Corporation

CONMED Corporation is a medical technology company. The Company is engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. The Company provides surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and physicians in a range of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology.

Earnings History for CONMED Corporation (NASDAQ:CNMD)

Receive News & Ratings for CONMED Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED Corporation and related companies with's FREE daily email newsletter.